Insider · CIK 0001956391
Josh Riggs
Files at IMDX (Oncocyte Corp). First filing Apr 15, 2024, latest Apr 15, 2024.
In brief
Josh Riggs files SEC Form 4 as CEO, president and director at IMDX (Oncocyte Corp). Since Apr 15, 2024, Josh Riggs has reported 1 open-market buy worth $10k and 0 open-market sells worth $0, the latest filed on Apr 15, 2024.
A track record needs three past buys with six months of prices behind them; Josh Riggs has 0, so none is measured yet.
The newest scored trade: bought $10k of IMDX on Apr 11, 2024, filed Apr 15, 2024, scored 58 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IMDX: Oncocyte Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Oncocyte Corp | $10k 3,390 shares | +2948% | +43% from low-57% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | IMDX Oncocyte Corp | MOption exercise Common Stock | +47,170 | - | - | 50,675 | Mar 30, 2026 |
| Mar 26, 2026 | IMDX Oncocyte Corp | FTax withholding Common Stock | -12,310 | $4.11 | $51k | 38,365 | Mar 30, 2026 |
| Mar 26, 2026 | IMDX Oncocyte Corp | MOption exercise Restricted Stock Unitsderivative | -47,170 | $0.00 | $0 | 141,509 | Mar 30, 2026 |
| Sep 28, 2025 | IMDX Oncocyte Corp | AGrant or award Option to Purchase Common Stockderivative | +400,000 | $0.00 | $0 | 400,000 | Sep 30, 2025 |
| May 20, 2024 | IMDX Oncocyte Corp | AGrant or award Option to Purchase Common Stockderivative | +90,000 | $0.00 | $0 | 90,000 | May 22, 2024 |
| Apr 11, 2024 | IMDX Oncocyte Corp | POpen-market purchase Common Stock, no par value | +3,390 | $2.95 | $10k | 3,505 | Apr 15, 2024 |
Questions about Josh Riggs
Answered from the filings on this page, as of the latest one.
Is Josh Riggs buying or selling?
Not in the last 12 months. Josh Riggs's latest open-market trade on SEC Form 4 was bought $10k of IMDX on Apr 11, 2024.
How did Josh Riggs's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Josh Riggs has 0.
Where does Josh Riggs file Form 4?
Josh Riggs has filed Form 4 at IMDX (Oncocyte Corp) as CEO and President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.